title: Selumetinib shows promise in metastatic uveal melanoma.
abstract: Compared with temozolomide chemotherapy, the MEK inhibitor selumetinib extended progression-free survival by nearly 9 weeks in patients with melanoma of the eye participating in a phase II trial, making it the first effective drug for the rare disease.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D000077204:Temozolomide; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000098943:Uveal Melanoma
chemical_list: C517975:AZD 6244; D001562:Benzimidazoles; D003606:Dacarbazine; D000077204:Temozolomide